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The subcellular localization of proteins is critical to their biological roles. Moreover, whether a protein is membrane-
bound, secreted, or intracellular affects the usefulness of, and the strategies for, using a protein as a diagnostic marker
or a target for therapy. We employed a rapid and efficient experimental approach to classify thousands of human gene
products as either ‘‘membrane-associated/secreted’’ (MS) or ‘‘cytosolic/nuclear’’ (CN). Using subcellular fractionation
methods, we separated mRNAs associated with membranes from those associated with the soluble cytosolic fraction
and analyzed these two pools by comparative hybridization to DNA microarrays. Analysis of 11 different human cell
lines, representing lymphoid, myeloid, breast, ovarian, hepatic, colon, and prostate tissues, identified more than 5,000
previously uncharacterized MS and more than 6,400 putative CN genes at high confidence levels. The experimentally
determined localizations correlated well with in silico predictions of signal peptides and transmembrane domains, but
also significantly increased the number of human genes that could be cataloged as encoding either MS or CN proteins.
Using gene expression data from a variety of primary human malignancies and normal tissues, we rationally identified
hundreds of MS gene products that are significantly overexpressed in tumors compared to normal tissues and thus
represent candidates for serum diagnostic tests or monoclonal antibody-based therapies. Finally, we used the catalog
of CN gene products to generate sets of candidate markers of organ-specific tissue injury. The large-scale annotation of
subcellular localization reported here will serve as a reference database and will aid in the rational design of diagnostic
tests and molecular therapies for diverse diseases.
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Introduction
The subcellular localization of proteins critically affects
their biological roles and functions. For example, sequence-
speciﬁc DNA-binding proteins can only alter transcriptional
activity if they are localized to the nucleus, and trans-
membrane (TM) receptors can only bind their soluble ligands
if they are at least partially exposed to the extracellular
environment. Categorization of proteins by subcellular local-
ization is therefore one of the essential goals for functional
annotation of the human genome.
Proteins that are inserted into membranes or secreted are a
particularly important class, as they include signal trans-
duction receptors, transporters, channels, cell-to-cell signal-
ing molecules, extracellular matrix components, and
adhesion molecules. Surface and secreted proteins are also
of special relevance to many areas of medicine. Plasma
membrane proteins and secreted signaling proteins are
candidate targets for monoclonal antibody-based therapies
[1]. There are already more than ten Food and Drug
Administration-approved monoclonal antibody therapeutics
and dozens more in clinical development. Some of these,
including Trastuzumab (Herceptin), Rituximab (Rituxan),
and Cetuximab (Erbitux), target TM proteins on the surface
of malignant cells and have ﬁrmly established their value in
the treatment of cancer. Secreted and shed proteins with
tumor- or disease-speciﬁc expression patterns represent
potential targets for diagnostic assays in biological ﬂuids.
Such assays are currently being used to screen patients for
diagnosis or detection of recurrence of a number of
malignancies, including prostate, ovarian, and liver cancer
[2]. Conversely, intracellular proteins that are released into
the extracellular space with cell injury or death provide the
basis for sensitive assays to diagnose speciﬁc organ injury
(e.g., troponins, creatine kinase, myosin, and transaminases)
[3]. Large-scale identiﬁcation of surface, secreted, and intra-
cellular proteins that are speciﬁc to organs, tissues, or disease
thus has great potential value in facilitating the further
development of these therapeutic and diagnostic approaches.
A variety of empirical and computational approaches has
been developed for identifying membrane and secreted
proteins. Commonly employed experimental approaches
include the signal-sequence trap [4,5], the signal-exon trap
[6], and construction of cDNA libraries from membrane-
associated mRNAs [7]. Computational approaches for pre-
dicting the presence of signal peptides (SPs) in protein
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works, and hidden Markov models (reviewed in [8]). Similarly,
algorithms to identify putative TM domains include sliding
window methods, neural networks, and hidden Markov
models (reviewed in [9]). Both the experimental and the
computational approaches are imperfect, and combining
information from different methods will likely improve
sensitivity and speciﬁcity. In that respect, a major limitation
of most of the empirical methods is that they are not designed
to be used on a genome-wide scale. Although the existing
methods focus on identifying membrane-associated/secreted
(MS) proteins, it would also be useful to systematically
identify probable cytosolic/nuclear (CN) proteins.
We set out to classify thousands of human genes as
encoding either MS or CN proteins, using a previously
described genome-scale method [10]. Brieﬂy, this method
takes advantage of the consistent (though not universal [11])
difference in the subcellular location at which these two
classes of proteins are translated. Most MS proteins are
translated by polyribosomes bound to the cytoplasmic face of
the endoplasmic reticulum (ER), while most CN proteins are
translated on polyribosomes in the cytoplasm. The mRNAs
corresponding to these two classes of proteins can therefore
be separated by sedimentation equilibrium based on their
association with microsomes [12] and can subsequently be
analyzed using cDNA microarrays.
Using this approach, we identiﬁed more than 5,000 putative
MS and more than 6,400 putative CN genes (UniGene
clusters). Our annotations agreed well with in silico methods
for predicting localization, but also included thousands of
genes for which such predictions were not available. One
advantage of our approach was the ability to directly apply
our categorizations to microarray gene expression data from
hundreds of primary tumor and normal tissue samples that
were generated separately using the same DNA microarrays.
We were thus able to identify hundreds of genes that showed
tumor-speciﬁc expression patterns and that are highly likely
to encode MS proteins. These data provide a foundation for
the development of targeted therapies and diagnostic tests for
a wide variety of human malignancies.
Results
Identification of MS- and CN-Encoding Genes
Based on previously reported microarray experiments [13],
we chose a panel of 11 cell lines whose gene expression
patterns would, in aggregate, encompass a large set of mRNAs
(Table S1). RNAs in the membrane and cytosolic fractions of
each cell line were separated using a previously described
sedimentation equilibrium method [10], and ﬂuorescently
labeled cDNA was generated from each fraction. For every
cell line, we labeled cDNA from membrane-associated RNA
with Cy5 and cDNA from cytoplasmic RNA with Cy3, mixed
these, and hybridized them to DNA microarrays containing
up to approximately 42,000 elements (representing approx-
imately 32,500 UniGene clusters). For a subset of the cell
lines, we ﬁrst ampliﬁed the fractionated RNAs using a linear
ampliﬁcation method [14]. Several cell lines were fractionated
more than once; the results from a total of 19 hybridizations
were used for further analysis.
The thousands of genes represented on the microarrays for
which the subcellular localizations of the protein products
have previously been identiﬁed provided internal standards
for assessing the success of each fractionation and for
determining the conﬁdence with which an uncharacterized
gene could be classiﬁed as MS or CN. Genes encoding
proteins inserted into cellular membranes or that are
secreted were designated as the ‘‘MS reference set,’’ while
genes encoding cytoplasmic or nuclear proteins were
designated as the ‘‘CN reference set.’’ Limiting our search
to the 24,365 UniGene clusters that were detectably expressed
in at least three of the samples, we used empirical localization
data reported in the Swiss-Prot [15] and LocusLink [16]
databases to identify 2,701 known MS clusters and 2,744
known CN clusters. We then estimated the percentage of
mRNAs encoding MS proteins as a function of the Cy5/Cy3
ratio for each array, based on the data for these reference
gene sets [10]. Figure 1A displays the results of this analysis
for two of the fractionations. Genes for which we found the
highest Cy5/Cy3 ratios were highly enriched for those
encoding known MS proteins, while genes with the lowest
Cy5/Cy3 ratios were highly enriched for those encoding CN
proteins.
To estimate the number of novel MS or CN genes that were
identiﬁed by each additional fractionation, we calculated the
total number of unique cDNA clones that were more than
85% enriched in the membrane or cytosolic fraction on at
least one array. As show in Figure 1B, the rate at which
additional genes were classiﬁed dropped off signiﬁcantly with
each successive cell line analyzed. Nevertheless, a consider-
able number of novel genes continued to be classiﬁed with
each new analysis, and these genes are likely to encode cell-
type-speciﬁc markers that were not expressed in the preced-
ing cell lines. It is likely that by extending our approach to
include even more cell lines or tissues, we could substantially
increase the total number of genes classiﬁed as MS or CN.
In order to enable more complex analyses, we next
attempted to catalog the largest possible number of MS and
CN genes. To do so, we calculated various descriptive
statistics (median, mean, minimum, maximum, etc.) for a
number of parameters for every clone across all arrays,
including: the local percentage of characterized MS genes
based on the moving average analysis (see above), the base 2
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Synopsis
An important goal of current biological research is annotation of
human genes with relevant descriptors and properties. One critical
property of interest to biologists and medical researchers is the
subcellular localization of gene products, as this affects a protein’s
biological role and our ability to use it as a therapeutic target. This
study used a microarray-based functional genomic method that
allows rapid, large-scale identification of subcellular localization,
enabling the authors to annotate the localization of thousands of
previously uncharacterized human gene products. The authors then
provide an example of how these data can be used by applying
them to the search for tumor-specific markers. Using data from
hundreds of DNA microarray profiles of global gene expression
patterns in tumors and normal tissues, they identify candidate genes
encoding membrane-associated and secreted proteins that are
highly overexpressed in tumors and that might therefore be
particularly good targets for diagnostic tests or molecular therapies.
Diagnostic tests based on these markers could potentially enable
cancers to be detected earlier than is currently possible, and
molecular therapies targeting the products of these genes could
have high specificity for the corresponding cancers.logarithm of the Cy5/Cy3 ratio, the ratio of intensity to local
background for both Cy3 and Cy5, and the background-
subtracted intensity for both Cy3 and Cy5. As a ﬁnal
parameter, we included the ratio of the sum of Cy5
background-corrected intensities to the sum of Cy3 back-
ground-corrected intensities across all arrays. To identify the
best classiﬁcation approach, receiver–operator curves were
generated using each of these parameters (Figure 2A and 2B
and data not shown). Based on these calculations, we chose
the average log2 Cy5/Cy3 ratio as the metric for our
subsequent analyses. Clones were ranked in descending order
of the average log2 Cy5/Cy3 ratio, and a moving average
approach was used to identify the local percentage of
characterized MS/CN proteins at each end of this distribu-
tion. Since a subset of the UniGene clusters included on the
arrays was represented by two or more elements, we removed
all clusters with ambiguous localizations (i.e., clusters that
contained clones classiﬁed as both MS and CN). As expected,
relaxing the local percentage enrichment allowed annotation
of an increasingly larger set of unknown clones, but at the
expense of speciﬁcity (Figure 2C and 2D). Based on these
results, we chose two enrichment cutoffs for further analysis
(see Dataset S1), and the results for the less stringent of these
are summarized in Table 1. Including genes with known
localization, we were able to classify 60% of UniGene clusters
that passed minimum expression-level ﬁlters in at least one of
the fractionations (15,360 out of 24,365).
Comparison of In Silico and Empirical Classifications
We next compared our classiﬁcations with in silico
algorithms for protein localization prediction. Algorithms
that predict TM domains and SPs are particularly relevant to
the distinction between CN and MS proteins. Using all
UniGene clusters for which we obtained high-quality data and
for which full-length, curated NP protein sequences were
available in LocusLink, we analyzed the concordance between
our empirical method and the two prediction algorithms. As
shown in Figure 3A, there was a strong association between
the distribution of predicted SPs and TM domains and our
empirical annotations. The putative MS proteins identiﬁed by
our empirical method contained a slightly higher fraction of
predicted TM domains and SPs than the set of MS proteins
curated from published sources. For the set of CN proteins
identiﬁed by our method, the fraction that were predicted to
contain TM domains or SPs was marginally higher than the
set of CN proteins curated from published sources, consistent
with the slightly higher rate of contamination seen in Table 1.
This striking concordance between the two approaches
corroborates the accuracy of our experimental annotations.
As Figure 3B indicates, the empirically determined, in silico-
predicted, and curated/published sets were overlapping but
Figure 1. DNA Microarray Analysis of Subcellular mRNA Populations
(A) Moving average analyses of the fraction of mRNAs encoding MS proteins. Data for two representative fractionations are shown. In each case, well-
measured array elements representing characterized genes were extracted, and the local enrichment for MS-encoding genes (window size¼151) was
calculated as a function of the Cy5/Cy3 ratio. The horizontal line represents the overall fraction of MS genes on the microarrays used in these
experiments.
(B) Discovery rate analysis for the identification of MS and CN genes. A representative microarray hybridization was chosen for each cell line and the
total nonredundant number of classified MS or CN genes (UniGene clusters) was calculated after each new fractionation.
DOI: 10.1371/journal.pgen.0020011.g001
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classiﬁed by the known or in silico methods were assigned
with high conﬁdence by our empirical method. Furthermore,
it is important to note that even among previously known MS
proteins, only 64% contained TM domains and/or SPs,
underscoring the limited sensitivity of the computational
methods and the need for experimental methods that can
efﬁciently identify this class of proteins.
Analysis of mRNAs with Unexpected Localization
While the majority of the mRNAs that encode known CN
or MS proteins were found in the expected fraction by our
procedure, the RNAs encoded by a small number of known
genes were assigned to the seemingly incorrect fraction. We
used GO-TermFinder [17] to measure the enrichment of
Gene Ontology annotations among this group. The subset of
genes whose protein products have been reported to be CN
and that were classiﬁed as MS by our method was not
enriched for any GO term, suggesting that, at least by this
metric, they did not differ signiﬁcantly from all other CN
genes. We focused further on the known CN genes that were
represented by multiple clones on the arrays and for which
the majority of clones were classiﬁed as MS by our method.
On further investigation, we found the curated information
on localization of the products of many of these genes to be
incomplete or incorrect. For example, stomatin, an integral
membrane protein exposed on the cytoplasmic surface of red
blood cells, and secretagogin, a secreted protein, carried GO
annotations suggesting cytoplasmic localization even though
evidence exists in the literature that they are most likely
translated on the rough ER [18,19]. This suggested that
Figure 2. Large-Scale Categorization of MS and CN Genes
We evaluated the ability of various array element-specific parameters to classify genes encoding MS (A) or CN (B) proteins, using receiver operator
analysis. Based on these analyses, we chose the average log2 Cy5/Cy3 ratio for assigning the final localization annotations (see text and Protocol S1). The
curves were generated by incrementally relaxing the parameter cutoff values to generate gene sets with varying fractions of known MS- or CN-
encoding genes. (C) Relationship between sensitivity, specificity, fraction of characterized genes encoding MS proteins, and the total number of clones
classified as MS, using the average log2 Cy5/Cy3 ratio as the selection criteria. The vertical arrows indicate two cutoffs used for subsequent analyses. (D)
Same as in (C) but for genes encoding CN proteins.
DOI: 10.1371/journal.pgen.0020011.g002
Table 1. Experimental Annotation of MS and CN Genes
Category Localization Total Known
MS
Known
CN
Unknown Percent
Correct
Clone MS 10,296 2,444 381 7,471 87
CN 14,160 686 3,030 10,444 82
UniGene cluster MS 7,084 1,692 337 5,055 83
CN 8,984 499 1,991 6,494 80
Genes were categorized based on the average log2 Cy5/Cy3 ratio across all fractionations as described in the text
(window size 100). Only genes with an intensity/background ratio greater than 2.5 in either channel in at least three
fractionations were included. Datasets were selected with a local enrichment cutoff of 0.74 (see Figures 2C and 2D
and Protocol S1 for details).
DOI: 10.1371/journal.pgen.0020011.t001
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known gene sets could increase the number of unknown
genes that can be annotated by the microarray method.
A second class of CN genes with discrepancies between
their reported localization and our results consisted of genes
that belonged to families in which other members had
documented MS localization. For example, retinol-binding
protein 5 (RBP5) was classiﬁed by our analysis as MS, but the
protein is cataloged as cytoplasmic by Gene Ontology. While
no other experimental data suggesting MS localization for
RBP5 have been reported, the closely related protein RBP4,
the serum retinol carrier, is a documented secreted protein
[20]. This suggests that RBP5 may also have a, as yet
unrecognized, secreted form.
A third class of CN genes encoding proteins reported to be
cytoplasmic or nuclear, but whose mRNAs fractionated with
membranes in our analysis, included genes encoding proteins
that function at or near cellular membranes, but are not
integral membrane components themselves. ACK1 and TXK,
two nonmembrane spanning kinases, were examples of this
class. The protein encoded by ACK1 is localized to clathrin-
containing vesicles [21], and the TXK protein binds lipid rafts
via a palmitoylated cysteine-string motif [22]. Other examples
included cyclin B3, whose family member cyclin B1 interacts
with the cytoplasmic domain of the TM receptor PTCH [23],
and cyclin E2, which has been shown to associate with
endosomes and the plasma membrane of hepatocytes [24].
Thus, some genes, previously reported to be CN proteins and
whose mRNAs were enriched in the membrane fraction,
encode proteins that function in the cytosol, but in close
association with membranes. The membrane association of
their transcripts may therefore reﬂect a novel RNA sorting
process that localizes the polyribosomes carrying mRNAs
encoding these proteins to membranes. In support of this
idea, recent evidence from yeast indicates that some RNA-
binding proteins preferentially associate with 39 untranslated
regions of mRNAs encoding membrane-associated proteins
[25]. A further mechanism by which proteins containing
membrane-binding domains or modiﬁcations (pleckstrin
homology domain, myristoylation, etc.) might be translated
by membrane-associated polyribosomes could involve the
cotranslational maturation of the membrane-binding do-
Figure 3. Comparison of Empirical Classifications of MS and CN Genes with In Silico Prediction Methods
(A) We were ableto retrieve curated, NP proteinaccessionsfor 5,504of the well-measured UniGeneclusterson our arrays. Theprediction algorithms used
were SignalP (HMM/Smean score method) [33] for SPs and TMHMM (first60 score cutoff greater than 10) [34] for TM domains. In order to calculate the
fraction of proteins within a category that contained a given motif, the overlap between that category and the genes with protein sequences was used.
(B) Venn diagrams showing the overlap between the empirically determined cDNA clones, clones with in silico predictions, and clones encoding
proteins with known subcellular localization. For this analysis, we were able to retrieve representative protein accessions for 10,006 cDNA clones from
UniGene and applied the prediction algorithms as in (A).
DOI: 10.1371/journal.pgen.0020011.g003
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membranes.
Another potential explanation for unexpected enrichment
of some CN gene transcripts in the membrane fraction
applies to genes whose transcripts are alternatively spliced,
with one splice form encoding a CN protein, while another
encodes an MS protein. This is the case for estrogen receptor
1 (ESR1), which is generally classiﬁed as encoding a CN
protein, but which our method classiﬁed as MS. While the
best characterized role for ESR1 is as a transcriptional
activator in the nucleus, several reports provide evidence for
an alternatively spliced variant that encodes a surface-
exposed membrane-bound protein that can participate in
signal transduction [20,26]. Interestingly, we also found the
mRNA encoding the progesterone receptor (PGR) to be
enriched in the MS fraction, suggesting that there may also be
a membrane-bound form of this nuclear hormone receptor.
We also investigated genes whose products were reported to
be secreted or localized to membranes but whose transcripts
were enriched in the CN fraction. Using GO-TermFinder
(Table S2) we found that this group of genes was statistically
signiﬁcantly enriched for being involved in vesicle and
protein transport when compared to all MS genes. Even more
strikingly than with the anomalously localized CN genes, a
large fraction of the apparently mislocalized transcripts were
actually due to incorrect assignment of genes to the MS group.
These misannotated genes included many genes encoding
cytoplasmic proteins that function at or near membranes,
such as GOSR2, STX17, and GNAS. Furthermore, genes
encoding proteins localized to peroxisomes were highly
overrepresented in this class. Both peroxisomal membrane
and matrix proteins have been shown to be translated on free
polyribosomes in the cytoplasm and are posttranslationally
inserted into peroxisomes [27]. Therefore, these proteins
never traverse the rough ER, consistent with our observation
of peroxisomal mRNAs in the cytosolic fraction. The similar,
unexpected enrichment of mRNAs encoding vesicle transport
proteins in the CN fractions suggests that a subset of these
proteins may also be incorporated into membranes post-
translationally, rather than entering them via the standard ER
cotranslational insertion mechanism. Such a posttranslational
translocation pathway for ER import has been previously
reported and may be present in all eukaryotes [28]. It is
interesting to note that the mRNA encoding SEC61B, one of
the components of the complex that binds ribosomes and
serves as the channel by which proteins are cotranslationally
inserted into the ER, was in this group.
Another class of membrane or secreted proteins whose
mRNA reproducibly fractionates with the cytosol was
represented by the small inducible cytokine subfamily E,
member 1 (SCYE1). This gene encodes a multifunctional
polypeptide with both cytokine and tRNA-binding activities.
Studies have shown that the tRNA-binding domain interacts
with aminoacyl-tRNA synthetases, while a different domain of
the protein, with inﬂammatory cytokine activity, is released
extracellularly by proteolysis in response to apoptotic stimuli
[29]. These examples indicate that a discrepancy between the
localization of an mRNA and that of its protein product can
point to important aspects of a gene’s biological role. Further
analysis of this group of mRNAs is therefore likely to uncover
new features of the subcellular localization of human mRNAs.
Estimation of the Fraction of MS Genes in the Human
Genome
A particularly striking result of these studies was that 44%
of the genes that we could classify were predicted from our
results to encode MS proteins (Table 1). Previous estimates of
the fraction of human genes that encode membrane or
secreted proteins are based on in silico predictions of SPs and
TM domains and have ranged from 15% to 30% [30–32],
implying that a substantial majority of genes encode proteins
localized in the nucleus or cytoplasm. In our own in silico
analyses using SignalP [33] and TMHMM [34], we found that
approximately 25% to 30% of full-length protein sequences
curated in LocusLink contained either a predicted TM
domain, an SP, or both. We attempted to estimate this
fraction more rigorously using our experimental data and the
following equation:
Approximate number of MS genes in genome ¼
(number of MS genes classiﬁed)
3 (1/fraction of known MS genes on
microarray classiﬁed as MS). (1)
This allowed us to estimate the number of genes encoding
MS proteins we would have expected to ﬁnd had we been able
to identify every one of them. In order to assess the robustness
of our estimate, we performed the calculation with two MS
gene sets, one derived from lower and the other from higher
stringency analyses of our localization data. Using both sets,
we estimated the total number of MS UniGene clusters
present on our arrays to be approximately 7,000. Given that
our arrays provided technically adequate data for 24,365
clusters, and assuming that these were representative of all
genes in the genome, our data suggest that approximately
30% of human genes encode MS proteins. Thus, our empirical
results are consistent with the upper extreme of the previous
computational predictions. This analysis implies that there
are likely to be thousands of still unrecognized surface-
exposed and secreted proteins that could serve as useful
diagnostic markers or therapeutic targets.
Membrane-Associated Tissue- and Tumor-Specific Markers
We were particularly interested in identifying potential
secreted or surface-exposed TM proteins that were more
highly expressed in one or more cancers than in most or all
normal tissues. These proteins are potential diagnostic
markers or targets for monoclonal antibody-based therapies.
We began with a list of putative membrane or secreted
proteins identiﬁed in this work (see http://microarray-pubs.
stanford.edu/mbp2). We removed from this list all of the
known genes encoding CN proteins that we had curated
earlier. We next added any gene encoding a membrane or
secreted protein that was identiﬁed by our previous database
searches but was not identiﬁed as such in our analysis. This
aggregate list contained approximately 7,300 putative genes
(UniGene clusters), represented on our microarrays by 12,030
cDNA clones (see Dataset S2).
The same DNA microarrays that we used to catalog genes
encoding MS or CN proteins have been used to proﬁle gene
expression in hundreds of human tumor samples and normal
tissues. We therefore assembled data from 745 microarray
analyses of human tumors and normal tissues, including
malignancies of the brain, breast, kidney, lung, stomach,
ovary, pancreas, soft tissues, testis, and hematopoietic system
[35–49], all of which were analyzed by comparative hybrid-
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reference RNA. Using hierarchical clustering [50] and our
aggregate MS gene list, we compared expression of genes
encoding MS proteins among these samples.
In order to examine the relationship between tumor and
normal specimens stemming from the same tissue, we ﬁrst
clustered centroid array vectors for each tumor and normal
class. Tumor and normal classes from the same tissue
generally clustered together on terminal branches, with a
few exceptions (see Figure S1). When individual arrays were
clustered, all tumor types formed discrete clusters, and all but
a few specimens clustered in these deﬁned tumor groups.
Tumor samples clustered near the corresponding normal
samples from the same tissue but generally did not
intermingle (data not shown). This indicates that the
expression patterns of genes encoding membrane or secreted
proteins deﬁne molecular signatures that can identify the
tissue origin of tumors and that the membrane compartments
of the tumors tend to be similar to, but distinct from, those of
the normal tissues from which they arose.
Figure 4 depicts the diverse, complex patterns of variation
in MS gene expression in the human tumor and normal
tissues that we examined. A signiﬁcant fraction of these genes
were expressed in tissue-speciﬁc patterns, reﬂecting the vast
qualitative differences between the membrane compartments
of cells stemming from different tumors. Genes encoding a
number of MS proteins that are currently used as cancer
markers or targets of therapeutic antibodies were identiﬁed
by our approach, including KLK3 (PSA), AFP, EGFR, ERBB2,
CEACAM5 (CEA), and VEGF. Their expression patterns were
generally consistent with previous studies. For example,
ERBB2 was especially highly expressed in a subset of breast
Figure 4. Expression of MS Genes in Human Malignancies and Normal Tissues
Gene expression profiles for 745 tumor and normal specimens were generated on the same types of microarrays used for the fractionation experiments.
Array elements representing MS genes that varied more than 3-fold from the median on at least three microarrays were included. The data are
displayed as a hierarchical cluster where rows represent genes (UniGene clusters) and columns represent experimental samples. Colored pixels capture
the magnitude of the response for any gene, where shades of red and green represent induction and repression, respectively, relative to the median for
each gene. Black pixels reflect no change from the median and gray pixels represent missing data. For clarity of display, tumor and normal samples for
each tumor type were hierarchically clustered separately and then arranged by the order derived from clustering their mean centroids (see Protocol S1).
The positions of several genes are indicated.
DOI: 10.1371/journal.pgen.0020011.g004
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epithelial tumors, including those of the breast, stomach, and
lung [51–53].
Identification of MS Tumor Markers
We next wished to identify potential therapeutic and
diagnostic targets that were expressed in a tumor-speciﬁc
fashion. Small molecule or monoclonal antibody-based
therapies have shown promise as single agents or in
conjunction with traditional modalities such as chemo-
therapy and radiotherapy, and it is likely that even better
tumor control and cure rates could be achieved by develop-
ing combinations of biologically based drugs for each tumor
type. The ideal class of markers for this approach consists of
surface-exposed and secreted proteins that are highly ex-
pressed in tumor cells and only minimally expressed in
normal tissues. The combination of our MS gene list and the
large-scale gene expression dataset we constructed allowed us
to rationally identify such candidate genes. We ranked genes
based on the difference between the median expression in
tumor samples of a given class and the 95th percentile
expression level across all normal tissue samples. This
resulted in selection of genes that were more highly expressed
in most of the tumor samples than in the vast majority of
normal tissues. To further prioritize candidate genes, we also
incorporated an estimate of transcript abundance into our
selection scheme, hypothesizing that more highly expressed
genes will make better therapeutic or diagnostic targets.
Since all of the microarray data presented here were
generated using a two-color comparative hybridization
approach that produces measurements of relative abundance
between different samples, we aimed to identify the relative
transcript abundance of potential candidate markers within
each tumor class. To estimate transcript abundance, we used
data from comparative hybridizations of the common
reference RNA used in each tumor experiment versus normal
female genomic DNA [48]. These data reﬂected the relative
abundance of each transcript in the reference and were used
to calculate a relative transcript abundance index for each
gene within each tumor subtype (see http://microarray-pubs.
stanford.edu/mbp2). This information can be used to help
prioritize genes for follow-up studies.
As shown in Figure 5, our approach identiﬁed a number of
genes that encode proteins that are targets of approved
cancer therapies, suggesting that many of our other candi-
dates may also represent useful therapeutic targets. For
example, our algorithm identiﬁed ERBB2 for ERBB2-positive
breast cancer [54], VEGF for renal cell carcinoma [55], and
MS4A1 (CD20) for non-Hodgkin’s lymphoma [56]. A cDNA
element representing EGFR was the top gene selected for
glioblastoma, where this gene has been shown to be the most
frequently ampliﬁed protooncogene [57]. For brain, breast,
and lung tumors, we subdivided the samples into the
previously known histologic and molecular subtypes of these
tumors [37,42]. Overlapping but distinct groups of genes were
selected for these subtypes (see http://microarray-pubs.
stanford.edu/mbp2). cDNA elements representing ERBB2
made up three of the top ﬁve elements selected for the
ERBB2 breast cancer subtype, but none of these were
included in the lists for basal and luminal breast cancers.
Conversely, CDH3, one of the known basal breast cancer
markers, was only identiﬁed as a strong marker for basal
breast tumors. These ﬁndings suggest that overlapping but
nonidentical cocktails of molecularly targeted drugs may
allow the best distinction between tumor and normal tissues
for various tumor subtypes. Among genes not previously well
known as tumor markers were several genes with expression
patterns highly speciﬁc for more than one tumor compared
to all normal tissues. These included the receptor tyrosine
kinase AXL, which was overexpressed in luminal breast,
testicular, and ovarian cancers. Genes such as AXL may
represent particularly fruitful candidates for biologically
based therapies, as they could potentially have activity against
a number of different tumors.
Identification of Markers of Organ-Specific Tissue Injury
Cytoplasmic and nuclear proteins that are expressed in a
tissue-speciﬁc fashion are potentially useful markers of
speciﬁc organ injuries that lead to their release into
extracellular spaces. Many such markers are currently used
in clinical medicine, including cardiac proteins such as
troponin and creatine kinase and ‘‘liver enzymes’’ such as
AST and ALT. We therefore assembled a list of approximately
8,500 putative CN genes (UniGene clusters), represented on
our DNA microarrays by 15,311 cDNA clones, using an
approach analogous to that used to assemble the aggregate
list of putative MS proteins in the previous section (see
Dataset S3). Focusing on data from 150 microarray analyses
of tissue samples representing 15 different normal tissues, we
used Student’s t-test to identify the 20 genes most consistently
expressed at a higher level in each of the tissues compared to
all others (Figure 6). We found corroborating evidence for the
relative tissue speciﬁcity of many of the genes that we
identiﬁed in the literature and in expressed sequence tag
abundance data available in SOURCE. For example, two of
the genes identiﬁed as being relatively highly expressed in
breast tissue were TFAP2C and KRT5. TFAP2C, also known as
AP-2c, plays a role in ERBB2 expression and has recently
been shown to be expressed speciﬁcally in myoepithelial cells
of the basal ductal and lobular breast epithelia [58], a pattern
similar to that of the better-characterized basal ductal marker
KRT5 [59]. Antibodies to a combination of these CN tissue-
speciﬁc markers may provide useful assays for detection and
diagnosis of such varying conditions as traumatic injury, fever
of unknown origin, early-stage acute lung injury, and
surveillance of metastasis in cancer patients.
Discussion
We have used DNA microarrays coupled with subcellular
fractionation of mRNAs to categorize thousands of genes as
either MS or CN. Our classiﬁcations agreed well with in silico
methods for predicting subcellular localization. The fact that
approximately 40% of all previously identiﬁed MS proteins,
andasimilarfractionofMSproteinsidentiﬁedinthiswork,do
not contain predicted SPs or TM domains underscores the
continuing importance of experimental approaches to deter-
mining the subcellular localization of proteins. It is important
to note that both the computational methods and our
microarray approach provide only indirect evidence for a
speciﬁc localization, ultimately requiring direct validation to
conclusively determine a protein’s localization. Annotation of
genes based on both experimental data and in silico
predictions will provide the surest assignments. Based on our
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encodeMSproteins,aproportionattheupperendofprevious
estimates [30–32]. This estimate is important, since it increases
the possible number of surface-exposed or secreted polypep-
tides that could serve as useful therapeutic or diagnostic
targets, and it highlights the importance of cell–cell commu-
nication and extracellular structures in human biology.
We identiﬁed a subset of genes encoding known MS or CN
proteins whose mRNAs fractionated in an unexpected
manner. While one common cause of this phenomenon was
incorrect or incomplete annotation of the localization of the
proteins encoded by these genes, we also identiﬁed intriguing
examples that reﬂected important aspects of the molecular
regulation and function of this class of genes. The presence of
genes encoding cytoplasmic proteins that function near
membrane structures in the group of CN-encoding tran-
scripts with unexpected membrane localization suggests that
cells actively sort mRNAs in order to promote their trans-
lation at sites where their encoded protein products are
required. A recent study in yeast showed that some RNA-
binding proteins speciﬁcally associate with mRNAs encoding
membrane-associated proteins [25], and a similar mechanism
may be contributing to the unexpected segregation of some
mRNAs that we observed.
The microarray-based approach we used to study sub-
cellular localizations of mRNAs can still be further developed
and reﬁned. Simply fractionating more cell lines and
extending the approach to whole tissues should allow the
classiﬁcation of many more genes. Technically, it may be
possible to reﬁne the speciﬁcity of the method by analyzing
only those transcripts in the MS and CN fractions that are
also associated with polyribosomes. Similarly, approaches
identifying mRNAs associated with subcellular organelles,
cytoskeletal elements, motor proteins, and RNA-binding
proteins will further our understanding of subcellular local-
ization of RNAs and uncover interesting aspects of the
biology of the proteins that they encode [25,60–63]. Micro-
array-based approaches can be particularly useful for
Figure 5. Identification of MS Tumor Markers
Array elements were ranked based on the difference between the median expression in tumor samples of a given class and the 95th percentile
expression level across all normal tissue samples. The dataset was selected in a similar fashion as for Figure 4 (see Protocol S1). Only array elements that
passed data quality filters for at least 40% of normal tissues and at least 50% of one or more tumor classes were considered. The top 50 genes for each
tumor class are shown, and the positions of several genes are indicated. Brain, lung, and breast tumors were divided into their previously known
histologic and molecular subtypes.
GBM, glioblastoma multiforme; oligo, oligoastrocytoma/oligodendroglioma; adeno, adenocarcinoma; SCC, squamous cell carcinoma.
DOI: 10.1371/journal.pgen.0020011.g005
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genomic or expression libraries exist, as in silico-based
approaches are not possible in this setting.
Using publicly available gene expression data, we identiﬁed
hundreds of MS genes with tumor-speciﬁc expression
patterns. The proteins encoded by these genes represent
promising targets for antibody- or small molecule-based
therapeutics, for blood based assays for early detection of
cancer, for monitoring of treatment responses, and for
detecting recurrence following treatment. While there was
prior evidence for tumor-speciﬁc expression of some of the
markers, we identiﬁed many novel tumor markers that
expand the catalog of potentially useful drug targets. Our
approach also allows rational prioritization of known and
novel markers for drug development based on relative
speciﬁcity of expression and absolute transcript abundance,
increasing the likelihood of developing successful therapies.
Our strategy could be reﬁned by developing methods to focus
separately on surface and secreted proteins, as these may be
better candidates for therapeutic and diagnostic markers,
respectively. Also, expansion of the number of tumor and
normal samples with large-scale gene expression data would
allow even better accuracy in selecting tumor-speciﬁc
markers. Our approach might also be extended to anticipate
and avoid molecular targets that would risk potential clinical
side effects, such as excluding genes highly expressed by
hematologic cells to limit bone marrow toxicity or by
excluding genes expressed by cardiac myocytes in order to
minimize cardiovascular toxicity. The combination of func-
tional annotations such as subcellular localization with
systematic data on gene expression in the gamut of normal
cells and tissues as well as cancers provides a basis for
improved approaches to drug design and diagnosis.
Materials and Methods
Subcellular fractionation and RNA isolation. The methods closely
followed those of a previous study [10]. Brieﬂy, we used equilibrium
density gradient centrifugation to separate free mRNA and mRNA
associated with the rough ER or other membrane structures from a
variety of human cell lines [12,64]. Total RNA was isolated from the
membrane and cytoplasmic fractions using TRIzol (Life Technolo-
gies, Carlsbad, California, United States). For a subset of cell lines, the
resulting products were ampliﬁed using a linear, in vitro tran-
scription-based, antisense RNA ampliﬁcation [14].
Microarray manufacture and hybridization. DNA microarrays were
produced and hybridized as previously described [65] (http://cmgm.
stanford.edu/pbrown). To quantitate the distribution of mRNAs
between the membrane and cytoplasmic fractions, Cy5-labeled cDNA
Figure 6. Identification of Markers of Organ-Specific Injury
The top-20 CN array elements for each normal tissue were selected using a Student’s t-test comparing each normal tissue to all other normal tissues. All
normal tissues represented by at least five microarray experiments in Figure 4 were included (150 microarrays). Only array elements that passed data
quality filters for at least 70% of all normal tissue experiments were considered. Data are displayed as in Figure 4, and the positions of several genes are
indicated.
DOI: 10.1371/journal.pgen.0020011.g006
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Cy3-labeled cDNA was prepared from RNA extracted from the
cytoplasmic complement. The cDNA microarrays were produced by
the Stanford Functional Genomics Facility and contained a set of
approximately 42,000 sequence-conﬁrmed cDNA clones, represent-
ing both characterized and uncharacterized genes. Raw images and
data from the experiments described here are available at http://
microarray-pubs.stanford.edu/mbp2 and the Stanford Microarray
Database [66].
Identiﬁcation of empirically determined membrane-associated
proteins. Information on experimentally determined subcellular
localization of protein products was collected for as many genes as
possible. Sources included literature searches and queries of
SOURCE [67] (http://source.stanford.edu), which includes subcellular
localization information from Swiss-Prot and LocusLink Gene
Ontology annotations [15,16,68]. Proteins documented to be secreted,
or localized to the ER, golgi, vesicles, or plasma membrane were
grouped together as MS, while genes coding for cytosolic or nuclear
proteins were designated as CN.
Bioinformatic analyses. Analyses were performed as described in
the text and ﬁgure legends. Perl scripts were used where necessary to
facilitate the analyses. For in silico predictions of localization, we
used the SignalP program (HMM/Smean score method) [33] for SPs
and the TMHMM program (ﬁrst60 score cutoff greater than 10) [34]
for TM domains. More detailed methods, the raw microarray data,
and a list containing our experimental gene-product localizations,
previously identiﬁed protein localization data, and in silico pre-
dictions for all genes examined can be found at our Web site (http://
microarray-pubs.stanford.edu/mbp2).
Supporting Information
Dataset S1. Clone Localization Data
Experimental, in silico, and known localization data for each well-
measured clone.
Found at DOI: 10.1371/journal.pgen.0020011.sd001 (7.2 MB XLS).
Dataset S2. MS Clones
List of 12,030 MS clones used for the analyses in Figures 4 and 5.
Found at DOI: 10.1371/journal.pgen.0020011.sd002 (156 KB TXT).
Dataset S3. CN Clones
List of 15,311 CN clones used for the analyses in Figure 6.
Found at DOI: 10.1371/journal.pgen.0020011.sd003 (196 KB TXT).
Figure S1. Relationship of Tumors and Normal Tissues Based on the
Expression of MS Protein Encoding Genes
In order to examine the relationship between tumor and normal
specimens stemming from the same tissue, mean centroids were
calculated for each tumor and normal tissue group. These were then
hierarchically clustered using average linkage clustering. Tumor and
normal classes from the same tissue generally clustered together on
terminal branches, with a few exceptions (germ cell, pancreatic,
ovarian).
Found at DOI: 10.1371/journal.pgen.0020011.sg001 (868 KB EPS).
Protocol S1. Supplemental Methods
Found at DOI: 10.1371/journal.pgen.0020011.sd004 (60 KB DOC).
Table S1. List of Cell Lines Used in This Study
The table lists the tissue of origin for each line and its ATTC catalog
number (where available).
Found at DOI: 10.1371/journal.pgen.0020011.st001 (30 KB DOC).
Table S2. Gene Ontology (GO) Category Enrichment among MS
Genes with Unexpected Subcellular Localization
Overrepresentation of GO annotations among characterized MS
genes, whose transcripts were enriched in the cytosolic fraction
compared to all characterized MS genes, is shown. Corrected p-values
were calculated using GO-TermFinder.
Found at DOI: 10.1371/journal.pgen.0020011.st002 (48 KB DOC).
Accession Numbers
The Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼gene) accession numbers for the genes and proteins
discussed in this paper are AFP (174), AXL (558), CDH3 (1001),
CEACAM5 (1048), cyclin B1 (891), cyclin B3 (85417), cyclin E2 (9134),
EGFR (1956), ERBB2 (2064), ESR1 (2099), GNAS (2778), GOSR2
(9570), KLK3 (354), KRT5 (3852), MS4A1 (2206), PGR (5241), PTCH
(5727), RBP4 (5950), RBP5 (83758), SCYE1 (9255), secretagogin
(10590), SEC61B (10952), stomatin (2040), STX17 (55014), TFAP2C
(7022), and VEGF (7422).
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